peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01118052)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01118052 | Phase 2 | Nov 1, 2010 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1